Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.
企業コードINDV
会社名Indivior PLC
上場日Dec 24, 2014
最高経営責任者「CEO」Mr. Joseph J. (Joe) Ciaffoni
従業員数1030
証券種類Ordinary Share
決算期末Dec 24
本社所在地234 Bath Road
都市SLOUGH
証券取引所NASDAQ Global Select Consolidated
国United Kingdom
郵便番号SL1 4EE
電話番号448043791090
ウェブサイトhttps://www.indivior.com/en
企業コードINDV
上場日Dec 24, 2014
最高経営責任者「CEO」Mr. Joseph J. (Joe) Ciaffoni
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし